- TRADE NAME: Diacomit (Biocodex SA)
- INDICATIONS: treatment of seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam.
- HALF-LIFE: 4.5–13 hours
- FDA APPROVAL DATE: 08/20/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Clobazam - PREGNANCY: Based on animal data, may cause fetal harm
Please login to view the rest of this drug profile.
Page last updated 02/16/2024
